Pharma firm Pierre Fabre has joined the Embleema Health Blockchain Consortium. The aim of the Consortium is to create a platform to hold real-world data which can be used by firms and regulatory stakeholders to assess patient-engagement and intervention effectiveness.
The project uses a delocalised blockchain model which places control of individual records in the hands of patients who can decide who can have access to what pieces of their information.
The company’s hope is that using a ‘live’ database will reduce the delay between the generation of real-world data and its use in regulatory and patient access.
Blockchain technology offers some technical advantages for this application, however as MAP has previously observed, blockchain is not a silver bullet, and such a system will pose numerous challenges, chief among them ensuring the cyber-security of the data.